OBIO - NASDAQ
Orchestra BioMed Holdings, Inc.
$3.86
-0.52%Orchestra BioMed Holdings, Inc. operates as a biomedical innovation company. The company's flagship product candidates include BackBeat Cardiac Neuromodulation Therapy (CNT) for the treatment of hypertension; and Virtue Sirolimus AngioInfusion Balloon (SAB) for the treatment of atherosclerotic artery disease. Its products also comprise FreeHold retractors that are minimally invasive surgical device solutions. The company has a strategic collaboration with Medtronic for the development and commercialization of BackBeat CNT for the treatment of hypertension in pacemaker-indicated patients; and a strategic partnership with Terumo Corporation for the development and commercialization of Virtue SAB for the treatment of artery disease. Orchestra BioMed Holdings, Inc. is based in New Hope, Pennsylvania.
At a Glance
Live SnapshotOrchestra BioMed Holdings, Inc. Profit Bridge
Profitability Analysis
Gross Margin
Exceptional pricing power and cost management. The company retains over half of revenue after direct costs.
Operating Margin
Operating losses indicate the core business is unprofitable. Requires restructuring or revenue growth.
Net Profit Margin
Net losses indicate the company is burning cash. Sustainability depends on path to profitability.
Profitability Insight
Margin squeeze alert: Healthy gross margins but weak operating margins suggest excessive operating expenses. Cost optimization could unlock significant value.
Orchestra BioMed Holdings, Inc. Income Statement
OBIO • NASDAQ
| Orchestra BioMed Holdings, Inc. Income Statement | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 | Dec 2020 |
|---|---|---|---|---|---|---|
REVENUE | ||||||
33.5M | 2.6M | 2.8M | 3.5M | -782K | 5.7M | |
GROSS PROFIT | ||||||
(190K) | (204K) | (186K) | (322K) | (199K) | (145K) | |
33.3M | 2.4M | 2.6M | 3.2M | -981K | 5.6M | |
OPERATING INCOME | ||||||
(85.1M) | (66.7M) | (54.1M) | (35.9M) | (20.8M) | (24.3M) | |
(26.9M) | (23.9M) | (20.3M) | (13.9M) | (7.9M) | (10.8M) | |
(58.2M) | (42.8M) | (33.8M) | (21.9M) | (12.9M) | (13.5M) | |
-51.8M | -64.3M | -51.5M | -32.7M | -21.8M | -18.8M | |
PRE-TAX INCOME | ||||||
(1.1M) | (0.0) | (0.0) | (0.0) | (927K) | (0.0) | |
-1.1M | 3.4M | 3.8M | 50K | -927K | 331K | |
-1.1M | 3.3M | 2.4M | -951K | -1.2M | -2.6M | |
-53M | -61M | -49.1M | -33.6M | -23M | -21.4M | |
NET INCOME | ||||||
-53M | -61M | -49.1M | -33.6M | -23M | -21.4M |
SEC Filings
OBIO - Filing history and reports
| Filing Type | Filing Date | Period Ending | Fiscal Year | Actions |
|---|---|---|---|---|
10-Q 10-Q 2026 Q1 Q1 | May 12, 2026 | March 31, 2026 | 2026 | |
DEF 14A DEF 14A 2026 N/A | April 29, 2026 | June 23, 2026 | 2026 | |
10-K 10-K 2025 FY FY | March 12, 2026 | December 31, 2025 | 2025 | |
8-K 8-K 2026 N/A | February 13, 2026 | February 12, 2026 | 2026 | |
8-K 8-K 2026 N/A | January 12, 2026 | January 12, 2026 | 2026 | |
8-K 8-K 2025 N/A | November 13, 2025 | November 12, 2025 | 2025 | |
10-Q 10-Q 2025 Q3 Q3 | November 10, 2025 | September 30, 2025 | 2025 | |
S-3 S-3 N/A | October 31, 2025 | October 31, 2025 | ||
8-K 8-K 2025 N/A | October 30, 2025 | October 30, 2025 | 2025 | |
8-K 8-K 2025 N/A | October 28, 2025 | October 24, 2025 | 2025 |
Related Guides
Continue your OBIO research with focused valuation guides.
Research Paths
Snapshot
Start with context, operating signals, and key market metrics.
Value Model
Stress test fair value across bear, base, and bull assumptions.
Statements
Validate revenue quality, margins, and balance sheet durability.
Earnings Call
Read management commentary and compare it with reported outcomes.
Dividends
Check payout sustainability and long-term distribution behavior.
Analyst Expectations
Review consensus spread and where estimate risk is concentrated.